Compare AbbVie Inc (ABBV) vs Vanguard S&P 500 ETF (VOO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Vanguard S&P 500 ETF — how do they compare? AbbVie Inc trades at $253.85 (market cap $449.91B), while Vanguard S&P 500 ETF trades at $683.81. The key difference: AbbVie Inc pays a 2.72% dividend while Vanguard S&P 500 ETF pays none. Which is the better fit depends on your goals.
| ABBV | VOO | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $261.07 | $698.29 |
52-Week Low | $184.85 | $570.23 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
VOO, the Vanguard S&P 500 ETF, trades at $690.58, up 0.87% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF tracks the S&P 500, offering broad exposure to large-cap U.S. equities. Recent news highlights sector rotation and AI-driven market volatility, with strategists projecting further index gains. A dividend of $1.96 is scheduled for late June 2026.
The outlook for VOO remains positive given its diversification and the S&P 500's earnings momentum, though risks include tech sector concentration and potential market corrections. Long-term investors may find value in its low-cost, passive approach to U.S. equity exposure despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Vanguard S&P 500 ETF
VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.
Read more on VOO →
